Choose a language and wait for the translated text.
Shots:
Johnson & Johnson has entered into a definitive agreement to acquire Ollin Biosciences for $2.2B upfront, with potential regulatory & commercial milestones of up to ~$1.125B; closing is expected before the end of 2026
The acquisition adds OLN324, a P-III VEGF/Ang2 bispecific antibody with high Ang2 potency & a small minibody format, being developed for retinal vascular diseases incl. wet AMD & diabetic macular edema
Separately, Blackstone Life Sciences will pay J&J a total of $750M over multiple years to fully fund OLN324’s P-III development, in return for regulatory & sales milestones plus single-digit royalties
Ref: Business Wire | Image: Johnson & Johnson | Ollin Biosciences | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Johnson & Johnson to Acquire Ollin Biosciences for ~$3.3B to Expand its Ophthalmology Pipeline appeared first on PharmaShots.